{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T04:10:55Z","timestamp":1746850255791,"version":"3.40.5"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Talaromycosis is increasingly reported in HIV-uninfected, immunocompromised individuals in an endemic area. The aim of this study was to compare the characteristics and mortality associated with talaromycosis in adult immunocompromised individuals caused by the anti-interferon-gamma autoantibody (anti-IFN- \u03b3 AAb) with those of people living with HIV\/AIDS (PWHA).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A retrospective cohort study was conducted at Maharaj Nakorn Chiang Mai Hospital, Thailand, in adults with confirmed HIV infection or anti-IFN- \u03b3-AAbs diagnosed with talaromycosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Thirty-two patients with anti-IFN- \u03b3-AAbs and 235 PWHA were included. Patients with anti-IFN- \u03b3-AAbs were older and more likely to have comorbidities. PWHA were more likely to have constitutional symptoms, cough, dyspnea, diarrhea, splenomegaly, umbilicated skin lesions, abnormal chest radiographs, and fungemia. Patients with anti-IFN- \u03b3-AAbs were more likely to have skin lesions such as macule\/papules\/nodules, abscesses and Sweet\u2019s syndrome, as well as bone and joint infections and higher white blood cell counts. The time from first symptom to treatment was longer in patients with anti-IFN- \u03b3-AAbs (44.5 days vs. 30.0 days, p-value\u2009=\u20090.049). The 24-week mortality rate was 9.4% (3 patients) in patients with anti-IFN- \u03b3-AAbs and 15.3% (36 patients) in PWHA (p-value\u2009=\u20090.372).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The clinical features of talaromycosis in patients with anti-IFN- \u03b3-AAbs differed from PWHA. Clinicians in areas where talaromycosis is endemic should be aware of the different features of talaromycosis in patients with anti-IFN- \u03b3 AAbs.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pntd.0012992","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T18:08:54Z","timestamp":1746814134000},"page":"e0012992","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical features of talaromycosis in people living with HIV\/AIDS (PWHA) and patients with anti-interferon-\u03b3 autoantibodies"],"prefix":"10.1371","volume":"19","author":[{"given":"Kawisara","family":"Krasaewes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narootchai","family":"Patanadamrongchai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanhathai","family":"Kaewpoowat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiraprapa","family":"Wipasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saowaluck","family":"Yasri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antika","family":"Wongthanee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1241-5954","authenticated-orcid":true,"given":"Romanee","family":"Chaiwarith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"issue":"8915","key":"pntd.0012992.ref001","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(94)91287-4","article-title":"Disseminated Penicillium marneffei infection in southeast Asia","volume":"344","author":"K Supparatpinyo","year":"1994","journal-title":"Lancet"},{"issue":"24","key":"pntd.0012992.ref002","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1056\/NEJMoa1613306","article-title":"A trial of itraconazole or amphotericin B for HIV-associated talaromycosis","volume":"376","author":"T Le","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"pntd.0012992.ref003","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/hiv.13024","article-title":"Clinical epidemiology and outcome of HIV-associated talaromycosis in Guangdong, China, during 2011-2017","volume":"21","author":"RS Ying","year":"2020","journal-title":"HIV Med"},{"issue":"3","key":"pntd.0012992.ref004","article-title":"Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients","volume":"5","author":"JFW Chan","year":"2016","journal-title":"Emerg Microbes Infect"},{"issue":"4","key":"pntd.0012992.ref005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215581","article-title":"Clinical outcome and laboratory markers for predicting disease activity in patients with disseminated opportunistic infections associated with anti-interferon-\u03b3 autoantibodies","volume":"14","author":"N Angkasekwinai","year":"2019","journal-title":"PLoS One"},{"issue":"8","key":"pntd.0012992.ref006","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1111160","article-title":"Adult-onset immunodeficiency in Thailand and Taiwan","volume":"367","author":"SK Browne","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"pntd.0012992.ref007","article-title":"Anti-IFN-\u03b3 autoantibodies underlie disseminated Talaromyces marneffei infections","volume":"217","author":"J Guo","year":"2020","journal-title":"J Exp Med"},{"issue":"9","key":"pntd.0012992.ref008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076371","article-title":"Autoantibody to interferon-gamma associated with adult-onset immunodeficiency in non-HIV individuals in Northern Thailand","volume":"8","author":"P Wongkulab","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"pntd.0012992.ref009","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1186\/s12879-021-06255-9","article-title":"Clinical findings of Talaromyces marneffei infection among patients with anti-interferon-\u03b3 immunodeficiency: a prospective cohort study","volume":"21","author":"Z-M Chen","year":"2021","journal-title":"BMC Infect Dis"},{"key":"pntd.0012992.ref010","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/1471-2334-13-464","article-title":"Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study","volume":"13","author":"R Kawila","year":"2013","journal-title":"BMC Infect Dis"},{"key":"pntd.0012992.ref011","author":"Thai AIDS Society","year":"2020"},{"issue":"7","key":"pntd.0012992.ref012","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1128\/CVI.00053-10","article-title":"Disseminated penicilliosis, recurrent bacteremic nontyphoidal salmonellosis, and burkholderiosis associated with acquired immunodeficiency due to autoantibody against gamma interferon","volume":"17","author":"BS-F Tang","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"pntd.0012992.ref013","article-title":"Clinical features of talaromycosis in people living with HIV\/AIDS (PWHA) and patients with anti-interferon-\u03b3 autoantibodies.","author":"K Kawisara","year":"2023"},{"issue":"10","key":"pntd.0012992.ref014","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/myc.13295","article-title":"Talaromyces marneffei infection in non-HIV-infected patients in mainland China","volume":"64","author":"L He","year":"2021","journal-title":"Mycoses"},{"issue":"1","key":"pntd.0012992.ref015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/cid\/ciz786","article-title":"Natural history and evolution of anti-interferon-\u03b3 autoantibody-associated immunodeficiency syndrome in Thailand and the United States","volume":"71","author":"GH Hong","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pntd.0012992.ref016","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/jof8020200","article-title":"Talaromyces marneffei infection: virulence, intracellular lifestyle and host defense mechanisms","volume":"8","author":"K Pruksaphon","year":"2022","journal-title":"J Fungi (Basel)"},{"issue":"9","key":"pntd.0012992.ref017","first-page":"2053","article-title":"Leukocytosis: basics of clinical assessment","volume":"62","author":"N Abramson","year":"2000","journal-title":"Am Fam Physician"},{"issue":"6","key":"pntd.0012992.ref018","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s11046-019-00410-2","article-title":"Talaromycosis (Penicilliosis) due to Talaromyces (Penicillium) marneffei: insights into the clinical trends of a major fungal disease 60 years after the discovery of the pathogen","volume":"184","author":"C Cao","year":"2019","journal-title":"Mycopathologia"},{"issue":"5","key":"pntd.0012992.ref019","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/BF00209535","article-title":"In vitro susceptibility of mycelial and yeast forms of Penicillium marneffei to amphotericin B, fluconazole, 5-fluorocytosine and itraconazole","volume":"9","author":"AS Sekhon","year":"1993","journal-title":"Eur J Epidemiol"},{"issue":"11","key":"pntd.0012992.ref020","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1128\/AAC.37.11.2407","article-title":"Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens","volume":"37","author":"K Supparatpinyo","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"pntd.0012992.ref021","first-page":"688","article-title":"An efficacy study of itraconazole in the treatment of Penicillium marneffei infection","volume":"75","author":"K Supparatpinyo","year":"1992","journal-title":"J Med Assoc Thai"},{"issue":"4","key":"pntd.0012992.ref022","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/clinids\/14.4.871","article-title":"Penicillium marneffei infection in patients infected with human immunodeficiency virus","volume":"14","author":"K Supparatpinyo","year":"1992","journal-title":"Clin Infect Dis"},{"key":"pntd.0012992.ref023","author":"Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers\u00a0for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America."},{"issue":"2","key":"pntd.0012992.ref024","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cmi.2018.04.018","article-title":"Effects of Talaromyces marneffei infection on mortality of HIV\/AIDS patients in southern China: a retrospective cohort study","volume":"25","author":"J Jiang","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"pntd.0012992.ref025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1742-6405-9-24","article-title":"Clinical characteristics and outcome of Penicillium marneffei infection among HIV-infected patients in northern Vietnam","volume":"9","author":"M Larsson","year":"2012","journal-title":"AIDS Res Ther"},{"issue":"1","key":"pntd.0012992.ref026","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s15010-021-01679-6","article-title":"Analysis of clinical characteristics and prognosis of talaromycosis (with or without human immunodeficiency virus) from a non-endemic area: a retrospective study","volume":"50","author":"Q Shen","year":"2022","journal-title":"Infection"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0012992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T18:09:13Z","timestamp":1746814153000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0012992"}},"subtitle":[],"editor":[{"given":"Thuy","family":"Le","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0012992","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]}}}